Last Day of Dealings

BiVictriX Therapeutics PLC

10 September 2024

 

BiVictriX Therapeutics plc

("BiVictriX", "BiVictriX Therapeutics" or the "Company")

Last Day of Dealings

Alderley Park, 10 September 2024 - BiVictriX (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst reducing treatment-related toxicities, today provides a further update with regards to the cancellation of admission of the Company's ordinary shares to trading on AIM (the "Cancellation"), as originally announced on 12 August 2024, and as approved by shareholders at the general meeting held on 29 August 2024.

Shareholders are reminded that the last day of trading in the Ordinary Shares on AIM is today, 10 September 2024, and Cancellation will become effective at 7:00 a.m. on 11 September 2024. Following Cancellation, the Company will re-register as a private company under the name BiVictriX Therapeutics Limited.

As previously announced, the Company has engaged JP Jenkins (https://jpjenkins.com), a firm Authorised and Regulated by the Financial Conduct Authority (FRN 950991), to operate a matched bargain facility for the trading of ordinary shares. This facility will allow existing shareholders of the Company and new investors to trade ordinary shares by matching buy and sell orders. Further details can be found on the Company's website www.bivictrix.com. The JP Jenkins facility will be effective for a minimum of six months from 11 September 2024. Investors may wish to register on https://jpjenkins.com and add BiVictriX Therapeutics Limited to their 'Watchlist' to continue to receive auction/price information and updates.

Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. Shareholders wishing to trade shares through JP Jenkins must do so through a stockbroker. A comprehensive list of stockbrokers who have signed up to access the JP Jenkins platform is available on request.

Following Cancellation, shareholders are encouraged to sign up to the Company's email news alerts via the BiVictriX website or to follow the Company on LinkedIn to stay updated on its continued development of next generation cancer therapeutics as a private company.

Further details regarding the cancellation and re-registration are set out in the circular sent to shareholders dated 12 August 2024. A copy of the circular is available on the Company's website www.bivictrix.com.

Following Cancellation, SP Angel Corporate Finance LLP will cease to act as nominated adviser and corporate broker to the Company, and Panmure Liberum Limited will cease to act as corporate broker to the Company.

Capitalised terms used but not defined in this announcement shall have the same meaning given to such terms in the Circular.

**ENDS**

For more information, please contact:

BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Michael Kauffman, Non-Executive Chairman	Email: [e-mail]
SP Angel Corporate Finance LLP (NOMAD and Broker) David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking)	Tel: [phone]
Panmure Liberum Limited (Joint Broker) Emma Earl, Freddy Crossley, Mark Rogers, Rupert Dearden	Tel: [phone]
ICR Consilium       Namrata Taak, Lucy Featherstone, Max Bennett, Emmalee Hoppe	Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni® Antibody Drug Conjugates ("ADCs") combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.

Find out more at www.bivictrix.com and connect with us on LinkedIn and Twitter @BiVictriX.

 

END